A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Status:
Recruiting
Trial end date:
2036-10-31
Target enrollment:
Participant gender:
Summary
Multi-center, open-label, first in human Phase 1 study of the safety, tolerability,
feasibility, and preliminary efficacy of the administration of genetically modified
autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor
(CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART-
TnMUC1 cells).